Suchergebnisse - "Rimassa, Lorenza"

PubPharm (17)

1

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Sangro, B. | Chan, S. | Kelley, R. | +123

2

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

3

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy : A global, observational study

enthalten in: Hepatology communications | 2023

von Joerg, V. | Scheiner, B. | D Alessio, A. | +33

4

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Vithayathil, M. | D'Alessio, A. | Fulgenzi, C. | +32

CommentIn: Liver Int. 2022 Nov;42(11):2352-2353. - PMID 36162086

5

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice : Results of the AB-real study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Fulgenzi, C. | Cheon, J. | D'Alessio, A. | +34

6

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis : A real-world study

enthalten in: Hepatology (Baltimore, Md.) | 2022

von D'Alessio, A. | Fulgenzi, C. | Nishida, N. | +32

CommentIn: Hepatology. 2022 Oct;76(4):906-908. - PMID 35491442

7

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kelley, R. | Rimassa, L. | Cheng, A. | +19

CommentIn: Lancet Oncol. 2022 Aug;23(8):962-963. - PMID 35798015

8

Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma : shedding light on the preclinical rationale and clinical trials

enthalten in: Expert opinion on investigational drugs | 2022

von Cammarota, A. | Zanuso, V. | D'Alessio, A. | +3

9

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score

enthalten in: Journal of hepatology | 2022

von Scheiner, B. | Pomej, K. | Kirstein, M. | +38

CommentIn: J Hepatol. 2022 Apr;76(4):987-988. - PMID 34780876

10

Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma : COSMIC-312 Phase III study design

enthalten in: Future oncology (London, England) | 2020

von Kelley, R. | W Oliver, J. | Hazra, S. | +4